Proactiveinvestors recommends
Additional Information
Market: AMEX
Sector: Pharmaceuticals & Biotechnology
EPIC: RNN
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Rexahn Pharmaceuticals
www.rexahn.com

Rexahn’s goal is to be a world-class biopharmaceutical company developing and delivering novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Leveraging a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling and nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Full Rexahn Pharmaceuticals profile here
Is RNN a Buy, Sell or Hold?Get your FREE analysis of RNN
Pdf

Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data at the American College of Neuropsychopharmacologists

9th Dec 2010, 12:25 pm

Rexahn Pharmaceuticals (NYSE AMEX:RNN), a clinical stage pharmaceutical company based in Rockville, Maryland, announced today that clinical data on the antidepressant activity of its Serdaxin drug were presented yesterday at the American College of Neuropsychopharmacologists Annual Meeting, held in Miami Beach, Florida.

The data, which comes from Serdaxin’s Phase IIa study, was presented by Joshua Rosenthal, one of the co-authors of the study.

The study’s results, which were first announced back in April by Rexahn, showed that patients with severe major depressive disorder taking 5 mg of Serdaxin had statistically significant improvement in Montgomery-Asberg Depression Rating Scale scores after 8 weeks of treatment, compared to a placebo. 

"Serdaxin represents a new mechanism and approach to anti-depression therapy by enhancing both the serotonin and dopamine activity of neural transmitters. We believe this approach has the potential to help a broader spectrum of patients than the currently marketed therapeutics," said Rick Soni, the Chief Operating Officer of Rexahn.

According to the company, Serdaxin has also shown neuroprotective potential in animals treated with neurotoxins, and may have important applications in the treatment of human neurodegenerative disorders such as Parkinson's disease and Alzheimer disease. Animal model studies also suggest that Serdaxin reduces aggressive behavior and relieves anxiety, Rexahn said.

The company said it plans to initiate a larger phase IIb clinical trial, involving about 300 patients, in the second half of 2010.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.